<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pediatric unipolar depression and pharmacotherapy: General principles</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pediatric unipolar depression and pharmacotherapy: General principles</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pediatric unipolar depression and pharmacotherapy: General principles</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Scott Moreland, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Liza Bonin, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H359205"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For children and adolescents with unipolar depression who are receiving pharmacotherapy, outcomes may be improved by following several general principles [<a href="#rid1">1-3</a>].</p><p>This topic reviews the general principles of administering pharmacotherapy to pediatric patients with depressive disorders. Other topics provide an overview of treating pediatric depression, and discuss choosing a specific antidepressant for depressed youth, psychosocial treatments for adolescent depression, and the effect of antidepressant medications on suicide risk in children and adolescents.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1228.html" rel="external">"Pediatric unipolar depression: Psychotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H2073770651"><span class="h1">CHOOSING TREATMENT FOR PEDIATRIC UNIPOLAR DEPRESSION</span><span class="headingEndMark"> — </span>Multiple treatment options, including pharmacotherapy and psychotherapy, are available for treating pediatric unipolar depression. (See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression"</a>.)</p><p class="headingAnchor" id="H358046"><span class="h1">PRESCRIBING PHARMACOTHERAPY</span><span class="headingEndMark"> — </span>The sections below describe the general principles of prescribing medications for pediatric unipolar depression.</p><p class="headingAnchor" id="H3227528"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Pharmacotherapy for unipolar depression is indicated for children and adolescents with moderate to severe depressive syndromes that are diagnosed according to the American Psychiatric Association's Diagnostic and Statistical Manual, Fifth Edition, Text Revision (DSM-5-TR) [<a href="#rid4">4</a>] or the World Health Organization's International Classification of Diseases-11<sup>th</sup> Revision (ICD-11) [<a href="#rid5">5</a>]. Indications include:</p><p class="bulletIndent1"><span class="glyph">●</span>Major depression  (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent depressive disorder (dysthymia)  (<a class="graphic graphic_table graphicRef91114" href="/d/graphic/91114.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Other specified depressive disorder (eg, depressive symptoms with functional impairment)</p><p></p><p>Other indications for antidepressants include depressive symptoms that accompany disorders that are amenable to pharmacotherapy (eg, anxiety disorders), as well as depressive syndromes that do not respond to psychotherapy. Medications are generally not used for patients who have subsyndromal depressive symptoms (minor depression) [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H358053"><span class="h2">Approach to the patient</span><span class="headingEndMark"> — </span>When initiating pharmacotherapy for depressed children and adolescents, clinicians should  (<a class="graphic graphic_table graphicRef62951" href="/d/graphic/62951.html" rel="external">table 3</a>) [<a href="#rid3">3,7,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Confirm the diagnosis of a unipolar depressive syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Help patients and families understand and accept pharmacotherapy by explaining the benefits and risks of antidepressants, as well as the risks of no treatment, and soliciting their preferences regarding different options.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allow enough time for patients and families to review the information about antidepressants to make informed decisions. Pharmacotherapy is not an emergency medical treatment for depressed children and adolescents.</p><p></p><p class="bulletIndent1">Although suicidal behavior is a medical emergency, the hurried administration of antidepressants has no role in the immediate, acute management of suicidal youth because antidepressants generally do not take effect for at least two to four weeks. (See  <a class="medical medical_review" href="/d/html/1230.html" rel="external">"Suicidal ideation and behavior in children and adolescents: Evaluation and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Establish that both the clinician and family need to monitor the patient. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conduct frequent interviews at the beginning of treatment (eg, once every week or two weeks), to foster the therapeutic alliance.</p><p></p><p class="headingAnchor" id="H358060"><span class="h2">Education</span><span class="headingEndMark"> — </span>Before pharmacotherapy is initiated for pediatric depression, clinicians, patients, and families should discuss the medication's benefits, safety risks, and potential side effects; the lag in onset of therapeutic effects; and criteria for discontinuation  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef77780" href="/d/graphic/77780.html" rel="external">table 5</a>) [<a href="#rid9">9</a>]. Education is part of obtaining assent from patients and informed consent from the parents or guardians. A useful resource for patients and parents that includes information about antidepressants, and is published by the American Academy of Child &amp; Adolescent Psychiatry and the American Psychiatry Association, is entitled <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aacap.org%2FApp_Themes%2FAACAP%2Fdocs%2Fresource_centers%2Fresources%2Fmed_guides%2FDepressionGuide-web.pdf&amp;token=nx%2BSLypk85dowa5dUHj9RC%2FdgphYw%2F9PXa6SLGgqZoWJz6d2gjLPuogpIi%2BRcvYfOogM%2Fm%2BS8QZFIuCzms5VyavjDaDdTdk8GnVqASKMhzu3FFoH%2BLmyGyGm09sH%2BENg&amp;TOPIC_ID=88735" target="_blank">Depression: Parents' Medication Guide</a> [<a href="#rid7">7</a>].</p><p>Education about pharmacotherapy should be developmentally appropriate for the patient's level of understanding [<a href="#rid3">3</a>]. In addition, education involves the families as partners of the treatment team and helps them understand the symptoms, causes, and treatment of depression; identify and manage dysphoria in the patient; address psychosocial deficits; and learn the importance of adherence with treatment. The clinical features and diagnosis of depression are discussed separately. (See  <a class="medical medical_review" href="/d/html/1224.html" rel="external">"Pediatric unipolar depression: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p>Discussion about the safety of antidepressants should include the US Food and Drug Administration (FDA) boxed warning in medication package inserts regarding suicidal ideation and behavior  (<a class="graphic graphic_table graphicRef54498" href="/d/graphic/54498.html" rel="external">table 6</a>) [<a href="#rid6">6,10</a>]. The warning requires clinicians to discuss its content before prescribing the medication and recommends monitoring for clinical worsening, such as increased suicidal ideation and behavior, or unusual changes after onset of treatment and dose changes. (See  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents", section on 'FDA black box warning'</a>.)</p><p>Patients and families should also be educated about the high risk of morbidity and mortality from untreated depression [<a href="#rid3">3,8</a>]. Following the advent of boxed warnings about antidepressants and suicidal ideation and behavior, studies of antidepressants in pediatric patients have concluded that the benefits of antidepressants under ordinary clinical circumstances outweigh the potential risk of suicidal ideation and behavior [<a href="#rid11">11</a>]. The adverse effects of untreated depression include the risk of suicide. (See  <a class="medical medical_review" href="/d/html/1229.html" rel="external">"Suicidal behavior in children and adolescents: Epidemiology and risk factors"</a>.)</p><p>Patient and family education about aspects of depression that are not specifically related to pharmacotherapy are discussed elsewhere in other topics. (See <a class="local">'Information for patients'</a> below and  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression", section on 'Education and resources'</a>.)</p><p class="headingAnchor" id="H358067"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>The initial assessment of depressed pediatric patients who are candidates for pharmacotherapy includes the following elements [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>History of present illness</p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms of depression, irritability, anxiety (particularly panic attacks), restlessness, agitation, and impulsivity </p><p class="bulletIndent2"><span class="glyph">•</span>Suicidal ideation and behavior</p><p class="bulletIndent2"><span class="glyph">•</span>Homicidal symptoms</p><p class="bulletIndent2"><span class="glyph">•</span>Psychotic features (eg, delusions or hallucinations)</p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid psychiatric disorders, including:</p><p class="bulletIndent3"><span class="glyph">-</span>Anxiety disorders</p><p class="bulletIndent3"><span class="glyph">-</span>Attention deficit hyperactivity disorder</p><p class="bulletIndent3"><span class="glyph">-</span>Substance related and addictive disorders</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Past psychiatric history (especially bipolar disorder)</p><p class="bulletIndent1"><span class="glyph">●</span>Psychosocial functioning</p><p class="bulletIndent1"><span class="glyph">●</span>Family history (especially parental history of depression and/or bipolar disorder)</p><p class="bulletIndent1"><span class="glyph">●</span>Social history, including family environment and ongoing negative life events (eg, family conflicts and abuse)</p><p class="bulletIndent1"><span class="glyph">●</span>General medical history</p><p class="bulletIndent1"><span class="glyph">●</span>Mental status examination</p><p></p><p>Using school years, birthdays, and holidays as anchor points, timelines can be established to help assess the onset and course of mood disorders. </p><p>If an underlying general medical condition (eg, hypothyroidism) is suspected, a physical examination and/or focused laboratory tests should be pursued in collaboration with the patient’s primary care clinician [<a href="#rid3">3</a>].</p><p>Confirming the diagnosis of unipolar depressive disorders includes ruling out bipolar disorder by checking for a past history of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 7</a>) and hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 8</a>). Episodes of major depression usually precede the first lifetime onset of manic and hypomanic episodes in bipolar disorder; thus, youth who initially present with a depressive syndrome may ultimately warrant a diagnosis of bipolar disorder. Patients with known bipolar disorder should first receive treatment with an antimanic drug prior to using an antidepressant and should not receive antidepressant monotherapy. (See  <a class="medical medical_review" href="/d/html/15924.html" rel="external">"Pediatric bipolar disorder: Clinical manifestations and course of illness", section on 'Major depression'</a> and  <a class="medical medical_review" href="/d/html/83083.html" rel="external">"Pediatric bipolar disorder: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p>In some cases, psychometric testing can be useful for children with learning problems or suspected intellectual disability. (See  <a class="medical medical_review" href="/d/html/613.html" rel="external">"Specific learning disorders in children: Evaluation", section on 'Psychometric tests'</a>.)</p><p>Further assessment depends upon the choice of antidepressant: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective serotonin reuptake inhibitor (SSRI), selective-norepinephrine reuptake inhibitor (SNRI), atypical antidepressant, or serotonin modulator </strong>– Generally, no pretreatment laboratory evaluation is necessary, other than a urine pregnancy test in postpubertal females who are not using reliable contraception. The potential risks of these antidepressants in pregnancy are discussed separately. (See  <a class="medical medical_review" href="/d/html/89067.html" rel="external">"Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"</a> and  <a class="medical medical_review" href="/d/html/100334.html" rel="external">"Antenatal use of antidepressants and risks of teratogenicity and adverse pregnancy outcomes: Drugs other than selective serotonin reuptake inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tricyclics</strong> – Tricyclics are rarely used to treat pediatric depression due to their general lack of efficacy in pediatric depression, unfavorable side effect profile  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 4</a>), required monitoring, and their lethality in overdose [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication", section on 'Choice of medication for acute treatment'</a>.)</p><p></p><p class="bulletIndent1">Before administering tricyclics to children and adolescents, clinicians should obtain the patient’s cardiac history and that of the family (first-degree relatives) [<a href="#rid3">3,10</a>]. The history includes symptoms associated with syncope, including dizziness, lightheadedness, or palpitations. For patients with a personal history of cardiac disease or a family history of premature (&lt;40 years of age) cardiac problems, a pediatric cardiology consult is warranted before starting tricyclics.</p><p></p><p class="bulletIndent1">In youth who are candidates for tricyclics, the pretreatment physical examination and laboratory tests include blood pressure, pulse, weight, and a baseline electrocardiogram (ECG) [<a href="#rid3">3,10</a>]. Tricyclics should not be initiated unless these parameters are within the normal limits for the child's age, sex, and height. Additional baseline tests include a pregnancy test for postpubertal females who are not using reliable contraception.</p><p></p><p class="bulletIndent1">Additional information about the baseline cardiac evaluation that is performed prior to initiating tricyclics and the effects of tricyclics in pregnancy are discussed separately. (See  <a class="medical medical_review" href="/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects", section on 'Cardiac evaluation'</a> and  <a class="medical medical_review" href="/d/html/100334.html" rel="external">"Antenatal use of antidepressants and risks of teratogenicity and adverse pregnancy outcomes: Drugs other than selective serotonin reuptake inhibitors", section on 'Tricyclic antidepressants'</a>.)</p><p></p><p class="headingAnchor" id="H358102"><span class="h2">Dose</span><span class="headingEndMark"> — </span>For children and adolescents, SSRIs are generally started at approximately one-half the usual adult dose  (<a class="graphic graphic_table graphicRef143262" href="/d/graphic/143262.html" rel="external">table 9</a>) for the first week of treatment. To minimize the chance of adverse events, we generally start with the minimum therapeutic dose [<a href="#rid6">6,12-14</a>]. After one week, the dose is increased within the lower therapeutic range. Doses are then titrated incrementally every two to four weeks, depending upon response and tolerability:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluoxetine</strong> – For adolescents, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> is started at 5 to 10 mg per day for one week and then increased to a target dose of 20 mg per day. After three weeks, if response is insufficient and the drug is tolerated, the dose is increased to 40 mg per day for the remainder of the drug trial. However, if a partial response occurs within four weeks of prescribing 40 mg per day, the dose is increased to 60 mg per day.</p><p></p><p class="bulletIndent1">For children, we start at 5 mg per day for one week and then titrate up to a target dose of 10 mg per day. After three weeks, if response is inadequate, we increase the dose to 20 mg per day for the remainder of the drug trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Citalopram</strong> – <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">Citalopram</a> is started at 10 mg per day for one week and then increased to a target dose of 20 mg per day. After three weeks, if response is insufficient and the drug is tolerated, the dose is increased to 30 mg per day for the remainder of the drug trial. However, if a partial response occurs within four weeks of prescribing 30 mg per day, we increase the dose to 40 mg per day.</p><p></p><p class="bulletIndent1">For patients who do not satisfactorily respond to 40 mg per day after four weeks, we discuss with the patient and family both the possibility of raising the dose further, as well as concerns that doses above 40 mg per day can cause QT interval prolongation. If they wish to continue <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, we obtain an ECG at 40 mg per day, prior to increasing the dose, and if the ECG is normal, we increase the dose to 50 mg per day and one week later, obtain another ECG.</p><p></p><p class="bulletIndent1">For patients who do not satisfactorily respond to 50 mg per day after four weeks, we discuss with the patient and family both the possibility of raising the dose to a maximum of 60 mg per day. If they wish to continue <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, we obtain an ECG at 50 mg per day, prior to increasing the dose, and if the ECG is normal, we increase the dose to 60 mg per day and one week later, obtain another ECG.</p><p></p><p class="bulletIndent1">Dose dependent QT interval prolongation with <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> is discussed separately. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Cardiac'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Escitalopram</strong> – <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">Escitalopram</a> is started at 5 mg per day for one week and then increased to a target dose of 10 mg per day. After three weeks, if response is insufficient and the drug is tolerated, the dose is increased to 20 mg per day for the remainder of the drug trial. However, if a partial response occurs within four weeks of prescribing 20 mg per day, we increase the dose to 30 mg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sertraline</strong> – <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> is started at 25 mg per day for one week and then increased to a target dose of 50 mg per day. After three weeks, if response is insufficient and the drug is tolerated, the dose is increased to 75 to 100 mg per day for the remainder of the drug trial. However, if a partial response occurs within four weeks of prescribing 75 to 100 mg per day, the dose may be increased by 25 to 50 mg per day every several (eg, three) weeks to a maximum dose of 200 mg per day.</p><p></p><p>We typically do not use <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> for pediatric depression because of its lack of demonstrated efficacy [<a href="#rid6">6,15,16</a>]. (See  <a class="medical medical_review" href="/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication", section on 'Other specific SSRIs'</a>.)</p><p>Symptoms typically begin to improve within two to four weeks after the target dose is achieved [<a href="#rid17">17</a>].</p><p>Although a meta-analysis of 13 randomized trials compared SSRIs with placebo in youth with unipolar major depression (n &gt;3000), and found no advantage for the maximum dose of the SSRI that was used, none of the studies were fixed-dose trials, which is the preferred method for studying dose effects [<a href="#rid17">17</a>]. In addition, studies in treatment-resistant pediatric depression suggest that higher doses of SSRIs may be superior to continued low doses [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H358109"><span class="h2">Duration of an adequate trial</span><span class="headingEndMark"> — </span>An adequate antidepressant trial in children and adolescents generally lasts 6 to 12 weeks. This includes the time to administer the starting dose for one week and to titrate the dose to the lower end of the therapeutic range for the next two to four weeks. If response is insufficient, and adherence is confirmed and the medication is tolerated, then the dose is increased to the middle of the therapeutic range [<a href="#rid11">11,20,21</a>]. However, if response remains insufficient over the next four weeks, the dose is increased to the upper end of the therapeutic range, provided it is tolerated. In some situations (eg, the drug is poorly tolerated), switching the medication is indicated and the duration of the trial is truncated [<a href="#rid12">12,13,22</a>].</p><p>Evidence supporting this approach includes a meta-analysis of 13 randomized trials lasting 8 to 12 weeks, which compared SSRIs (<a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>) with placebo in children and adolescents with unipolar major depression (n &gt;3000) [<a href="#rid17">17</a>]. Nearly 70 percent of the improvement with SSRIs occurred within the first two weeks of treatment, and minimal treatment gains were observed after four weeks of treatment.</p><p class="headingAnchor" id="H358116"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Clinicians prescribing pharmacotherapy for depressed pediatric patients, as well as families, should regularly assess symptoms, functioning, side effects  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef77780" href="/d/graphic/77780.html" rel="external">table 5</a>), adherence, and satisfaction with treatment [<a href="#rid3">3,7</a>]. The family should be educated about possible indicators of worsening depression, activation, and suicidality, and should notify clinicians if these symptoms occur because it may be necessary to further evaluate the patient and adjust the dose or switch to a different medication.</p><p>In particular, patients are monitored for the following adverse responses during the initial few months of therapy and when doses are increased or decreased [<a href="#rid13">13,23-25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening depressive symptoms (eg, suicidal ideation and behavior, anxiety, and insomnia)</p><p class="bulletIndent1"><span class="glyph">●</span>Agitation</p><p class="bulletIndent1"><span class="glyph">●</span>Irritability or hostility</p><p class="bulletIndent1"><span class="glyph">●</span>Impulsivity and disinhibition</p><p class="bulletIndent1"><span class="glyph">●</span>Akathisia (ie, restlessness and inability to sit down)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 8</a>) or mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 7</a>)</p><p></p><p>In addition, behavioral activation may occur with higher antidepressant concentrations or their rapid titration, and usually resolves when the antidepressant dose is decreased or stopped [<a href="#rid26">26,27</a>]. Serotonin syndrome can also occur when multiple serotonergic medications interact  (<a class="graphic graphic_table graphicRef64604" href="/d/graphic/64604.html" rel="external">table 10</a>), and usually requires hospitalization. (See  <a class="medical medical_review" href="/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p>We encourage clinicians to provide measurement based care, that is, monitor progress by serially measuring the severity of symptoms with a standardized scale [<a href="#rid6">6</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient Health Questionnaire – Nine Item (PHQ-9): Modified for Teens</strong> – The most widely used and studied depression scale among adults is the self-report PHQ-9. It can be used in adolescents [<a href="#rid28">28</a>]; however, there is a modified form of the PHQ-9 specifically for adolescents (PHQ-9: Modified for Teens)  (<a class="graphic graphic_table graphicRef104030" href="/d/graphic/104030.html" rel="external">table 11</a>) [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mood and Feelings Questionnaire</strong> – The Mood and Feelings Questionnaire is validated for both children and adolescents, and has a separate form that is completed by the patient and by the parent or caregiver about their offspring [<a href="#rid31">31-34</a>]. The patient and parent questionnaires are each available in a short version (13 items) and a long version (33 items for the patient, 34 for the parent); the short version lacks a question about suicidal ideation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quick Inventory of Depressive Symptomatology, Adolescent Version</strong> – The self-report, 17-item Quick Inventory of Depressive Symptomatology, Adolescent Version is another option for monitoring response to treatment [<a href="#rid35">35</a>].</p><p></p><p>Each of these measures is in the public domain [<a href="#rid36">36-38</a>].</p><p class="bulletIndent1">Additional information about measurement based care is discussed separately in the context of adults. (See  <a class="medical medical_review" href="/d/html/14860.html" rel="external">"Using scales to monitor symptoms and treat depression (measurement based care)"</a>.)</p><p></p><p>Patients treated with tricyclics require monitoring that includes blood pressure and pulse [<a href="#rid10">10</a>]. In addition, an ECG should be repeated in one week after the therapeutic dose is achieved, when the dose is changed, if the patient receives medications that can interact with tricyclics, if clinicians think the tricyclic serum concentration has changed, or following discontinuation of tricyclics. (Tricyclics can interfere with cardiac conduction and cause dose-dependent QTc prolongation.) If cardiac parameters are outside the normal limits for age, sex, and height, particularly in patients who are hypotensive or tachycardic, the dose should be decreased, and the ECG repeated. Consultation with a cardiologist is generally warranted in patients who respond to tricyclics, but manifest persistent ECG abnormalities. Specific interactions of tricyclics with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions tool</a> included in UpToDate.</p><p class="headingAnchor" id="H358123"><span class="h3">Frequency</span><span class="headingEndMark"> — </span>For outpatients who are treated with antidepressants, we typically interview patients and families weekly for the first four weeks at the onset of pharmacotherapy and when medications are switched [<a href="#rid8">8</a>]. Interviews can be conducted in person, or by videoconferencing or phone, but should include several in-person appointments within the first eight weeks of starting medication and as clinically necessary.</p><p>The frequency of follow-up at other times is individualized and can range from once every two weeks to once every three months. The schedule is based upon the severity of the depressive syndrome, level of social support, and the presence of comorbidity, adverse effects, and stressors (eg, break-up with girlfriend, death of a close relative, or poor school performance).</p><p class="headingAnchor" id="H358137"><span class="h2">Treatment-emergent suicidality</span><span class="headingEndMark"> — </span>Patients treated with antidepressants who experience severe suicidal ideation or suicidal behavior should be referred for emergency assessment to determine whether hospitalization is required. Once stabilized, patients are evaluated to determine the factors that led to the increased suicidality. Clinicians can then decide whether to adjust the antidepressant dose or switch to a different antidepressant from the same or a different class. The general consensus is that the benefits of antidepressants far outweigh the risk of suicidal events [<a href="#rid3">3,8</a>]. (See  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p class="headingAnchor" id="H358151"><span class="h1">DISCONTINUING PHARMACOTHERAPY</span><span class="headingEndMark"> — </span>Pharmacotherapy for pediatric depression generally lasts for at least 6 to 12 months after remission. (See  <a class="medical medical_review" href="/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication", section on 'Continuation and maintenance treatment'</a>.)</p><p>For patients who decide to stop antidepressants, prescribing clinicians should supervise discontinuation of treatment [<a href="#rid3">3</a>]. It is preferable to stop pharmacotherapy when psychosocial stress is reduced and the consequences of recurrences are reduced (eg, summer vacation).</p><p>Antidepressants should generally be tapered before discontinuation. A taper of approximately 25 to 50 percent per week provides a gradual decrease that allows the body time to adjust to the lower dose. As an example, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> 200 mg per day can be decreased to 150 mg per day for week one, 100 mg per day for week two, 50 mg per day for week three, and 25 mg per day for week four, after which the medication is stopped.</p><p>Abrupt discontinuation of selective serotonin reuptake inhibitors can cause a discontinuation (withdrawal) syndrome marked by:</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety</p><p class="bulletIndent1"><span class="glyph">●</span>Chills</p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue</p><p class="bulletIndent1"><span class="glyph">●</span>Myalgias</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea</p><p></p><p>Discontinuation symptoms may occur after just six to eight weeks of therapy. However, it is acceptable to abruptly stop <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> because its elimination half-life is long (4 to 16 days) [<a href="#rid39">39-41</a>].</p><p>Discontinuation of antidepressants is discussed further in the context of adults. (See  <a class="medical medical_review" href="/d/html/105323.html" rel="external">"Discontinuing antidepressant medications in adults"</a>.)</p><p class="headingAnchor" id="H2506318924"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H358158"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/140703.html" rel="external">"Patient education: Depression in children and teens (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4867.html" rel="external">"Patient education: Depression in children and adolescents (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4870.html" rel="external">"Patient education: Depression treatment options for children and adolescents (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p>Additional sources of information about unipolar major depression and treatment that is intended for patients and families is discussed separately. (See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression", section on 'Education and resources'</a>.)</p><p class="headingAnchor" id="H359455"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing treatment</strong> – Multiple treatment options, including pharmacotherapy and psychotherapy, are available for treating pediatric unipolar depression. (See  <a class="medical medical_review" href="/d/html/1231.html" rel="external">"Overview of prevention and treatment for pediatric depression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles of prescribing pharmacotherapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – Pharmacotherapy is indicated for children and adolescents diagnosed with moderate to severe major depression  (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 1</a>), persistent depressive disorder (dysthymia)  (<a class="graphic graphic_table graphicRef91114" href="/d/graphic/91114.html" rel="external">table 2</a>), or depressive symptoms with functional impairment, as well as nonresponse to psychotherapy. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Approach to the patient</strong> – Help patients and families understand and accept pharmacotherapy by explaining the benefits and risks of antidepressants, as well as the risks of no treatment, and soliciting their preferences regarding different options. Allow enough time for patients and families to review the information about antidepressants to make informed decisions. (See <a class="local">'Approach to the patient'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Education</strong> – Prior to starting antidepressants, clinicians should educate patients and families about depression, including its symptoms and available treatments. Clinicians should also discuss the benefits and side effects of pharmacotherapy  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef77780" href="/d/graphic/77780.html" rel="external">table 5</a>), the lag in onset of therapeutic effects, and the US Food and Drug Administration (FDA) boxed warning about suicidal ideation and behavior  (<a class="graphic graphic_table graphicRef54498" href="/d/graphic/54498.html" rel="external">table 6</a>). (See <a class="local">'Education'</a> above and  <a class="medical medical_review" href="/d/html/1225.html" rel="external">"Effect of antidepressants on suicide risk in children and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pretreatment evaluation</strong> – The initial assessment of depressed pediatric patients who are candidates for pharmacotherapy includes the history of present illness, past psychiatric history, family history, social history, general medical history, and mental status examination. If an underlying general medical condition is suspected, a physical examination and/or focused laboratory tests should be pursued in collaboration with the patient’s primary care clinician. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose</strong> – For children and adolescents, selective serotonin reuptake inhibitors (SSRIs) are generally started at approximately one-half the usual adult dose  (<a class="graphic graphic_table graphicRef143262" href="/d/graphic/143262.html" rel="external">table 9</a>) for the first week of treatment. This dose is increased after one week within the low therapeutic range. (See <a class="local">'Dose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of an adequate trial</strong> – An adequate antidepressant trial in children and adolescents lasts 6 to 12 weeks. (See <a class="local">'Duration of an adequate trial'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring</strong> – Clinicians and families should monitor patients who are treated with pharmacotherapy by assessing symptoms, including suicidal ideation and behavior, anxiety and panic attacks, agitation, irritability or hostility, impulsivity, and insomnia. Patients should also be monitored for hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 8</a>) or mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 7</a>), as well as medication side effects  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 4</a>) and adherence, psychosocial functioning, and satisfaction with treatment. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment-emergent suicidality</strong> – If patients treated with antidepressants experience suicidal behavior or sudden or severe suicidal ideation, they should be evaluated to determine if a higher level of care is necessary. Once stabilized, patients are assessed to determine what if any changes should be made regarding the antidepressant. (See <a class="local">'Treatment-emergent suicidality'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Discontinuation</strong> – Before discontinuing antidepressants, the dose is generally tapered by 25 to 50 percent per week to avoid discontinuation symptoms. However, it is reasonable to discontinue <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> abruptly. (See <a class="local">'Discontinuing pharmacotherapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management. Pediatrics 2018; 141.</a></li><li><a class="nounderline abstract_t">Zuckerbrot RA, Cheung A, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management. Pediatrics 2018; 141.</a></li><li class="breakAll">Lee ES, Findling RL. Principles of psychopharmacology. In: Dulcan's Textbook of Child and Adolescent Psychiatry, Third Edition, Dulcan MK (Ed), American Psychiatric Association Publishing, Washington, DC 2022. p.677.</li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li class="breakAll">World Health Organization. International Classification of Dieases 11th Revision. January 2022. https://icd.who.int/browse11/l-m/en (Accessed on October 03, 2023).</li><li class="breakAll">Emslie GJ, Stone LA, Jones JM. Antidepressants. In: Dulcan's Textbook of Child and Adolescent Psychiatry, Third Edition, Dulcan MK (Ed), American Psychiatric Association Publishing, Washington, DC 2022. p.729.</li><li class="breakAll">The American Academy of Child and Adolescent Psychiatry (AACAP) and the American Psychiatric Association (APA).  Depression: Parents’ Medication Guide. 2018. Available at: https://www.aacap.org/App_Themes/AACAP/docs/resource_centers/resources/med_guides/DepressionGuide-web.pdf (Accessed on June 28, 2023).</li><li class="breakAll">Birmaher B, Brent DA. Depressive and disruptive mood dysregulation disorders. In: Dulcan's Textbook of Child and Adolescent Psychiatry, Third Edition, Dulcan MK (Ed), American Psychiatric Association Publishing, Washington, DC 2022. p.245.</li><li class="breakAll">Birmaher B, Rengasamy M. Major depressive disorder. In: Clinical Manual of Child and Adolescent Psychopharmacology, Fourth Edition, McVoy M, Stepanova E, Findling RL (Eds), American Psychiatric Association Publishing, Washington, DC 2024. p.199.</li><li class="breakAll">Bloch MH, Beyer C, Martin A, Scahill L. Antidepressants. In: Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook, Fifth Edition, Martin A, Bloch MH, Volkmar FR (Eds), Wolters Kluwer, Philadelphia 2018.</li><li><a class="nounderline abstract_t">Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683.</a></li><li><a class="nounderline abstract_t">Walter HJ, Abright AR, Bukstein OG, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. J Am Acad Child Adolesc Psychiatry 2023; 62:479.</a></li><li class="breakAll">Cheung A.H., Zuckerbrot R.A., Jensen P.S., et al. GLAD-PC Toolkit Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC) Toolkit. 2018. Available at: www.gladpc.org (Accessed on June 20, 2023).</li><li><a class="nounderline abstract_t">MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. Can J Psychiatry 2016; 61:588.</a></li><li><a class="nounderline abstract_t">Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; 11:CD004851.</a></li><li><a class="nounderline abstract_t">Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015; 351:h4320.</a></li><li><a class="nounderline abstract_t">Varigonda AL, Jakubovski E, Taylor MJ, et al. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:557.</a></li><li><a class="nounderline abstract_t">Heiligenstein JH, Hoog SL, Wagner KD, et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol 2006; 16:207.</a></li><li><a class="nounderline abstract_t">Sakolsky DJ, Perel JM, Emslie GJ, et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol 2011; 31:92.</a></li><li><a class="nounderline abstract_t">Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 2008; 193:10.</a></li><li><a class="nounderline abstract_t">Lewandowski RE, Acri MC, Hoagwood KE, et al. Evidence for the management of adolescent depression. Pediatrics 2013; 132:e996.</a></li><li><a class="nounderline abstract_t">Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual Research Review: Defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry 2020; 61:312.</a></li><li class="breakAll">FDA. Labeling change request letter for antidepressant medications. Available at: www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm (Accessed on March 24, 2008).</li><li><a class="nounderline abstract_t">Lock J, Walker LR, Rickert VI, et al. Suicidality in adolescents being treated with antidepressant medications and the black box label: position paper of the Society for Adolescent Medicine. J Adolesc Health 2005; 36:92.</a></li><li class="breakAll">American Academy of Child and Adolescent Psychiatry. Supplementary talking points for child and adolescent psychiatrists regarding the FDA black box warning on the use of antidepressants for pediatric patients, November 2004. Available at: www.aacap.org/galleries/PsychiatricMedication/BlackBoxTalkingPoints.pdf (Accessed on March 24, 2008).</li><li><a class="nounderline abstract_t">Strawn JR, Mills JA, Poweleit EA, et al. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy 2023; 43:675.</a></li><li><a class="nounderline abstract_t">Luft MJ, Lamy M, DelBello MP, et al. Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management. Curr Probl Pediatr Adolesc Health Care 2018; 48:50.</a></li><li><a class="nounderline abstract_t">Nandakumar AL, Vande Voort JL, Nakonezny PA, et al. Psychometric Properties of the Patient Health Questionnaire-9 Modified for Major Depressive Disorder in Adolescents. J Child Adolesc Psychopharmacol 2019; 29:34.</a></li><li><a class="nounderline abstract_t">Johnson JG, Harris ES, Spitzer RL, Williams JB. The patient health questionnaire for adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients. J Adolesc Health 2002; 30:196.</a></li><li class="breakAll">Patient Health Questionnaire (PHQ)-9: Modified for Teens. Accessed at: https://www.nimh.nih.gov/research/research-conducted-at-nimh/asq-toolkit-materials/asq-tool/phq-9-modified-for-adolescents-phq-a (Accessed on June 26, 2023).</li><li><a class="nounderline abstract_t">Joinson C, Heron J, Araya R, Lewis G. Early menarche and depressive symptoms from adolescence to young adulthood in a UK cohort. J Am Acad Child Adolesc Psychiatry 2013; 52:591.</a></li><li><a class="nounderline abstract_t">Sund AM, Larsson B, Wichstrøm L. Prevalence and characteristics of depressive disorders in early adolescents in central Norway. Child Adolesc Psychiatry Ment Health 2011; 5:28.</a></li><li><a class="nounderline abstract_t">Wood A, Kroll L, Moore A, Harrington R. Properties of the mood and feelings questionnaire in adolescent psychiatric outpatients: a research note. J Child Psychol Psychiatry 1995; 36:327.</a></li><li><a class="nounderline abstract_t">Turner N, Joinson C, Peters TJ, et al. Validity of the Short Mood and Feelings Questionnaire in late adolescence. Psychol Assess 2014; 26:752.</a></li><li><a class="nounderline abstract_t">Haley CL, Kennard BD, Morris DW, et al. The Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A17): A Psychometric Evaluation. Neuropsychiatr Dis Treat 2023; 19:1085.</a></li><li class="breakAll">Patient Health Questionnaire (PHQ)-9: Modified for Teens. National Insititute of Mental Health. Available at: https://www.nimh.nih.gov/research/research-conducted-at-nimh/asq-toolkit-materials/asq-tool/phq-9-modified-for-adolescents-phq-a (Accessed on June 26, 2023).</li><li class="breakAll">Mood and Feelings Questionnaire. Child. Duke Psychiatry and Behavioral Sciences. Available at: http://devepi.duhs.duke.edu/mfq.html (Accessed on June 26, 2023).</li><li class="breakAll">QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY - ADOLESCENT (17 ITEM) – SELF REPORT. https://www.txhealthsteps.com/static/warehouse/1076-2010-Feb-4-y004q800nk422vp3hl9z/_documents/Psychiatric-QIDS-A17-SR-Adolescent-Self-Report.pdf (Accessed on December 24, 2023).</li><li><a class="nounderline abstract_t">Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901.</a></li><li><a class="nounderline abstract_t">Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165:459.</a></li><li class="breakAll">Rosenbaum JF, Ionescu DF. Fluoxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.335.</li></ol></div><div id="topicVersionRevision">Topic 88735 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483201" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483200" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17440145" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36273673" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36273673" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486149" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152227" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Newer generation antidepressants for depressive disorders in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26376805" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088660" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16553541" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21192150" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18700212" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy of antidepressants in juvenile depression: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24043282" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evidence for the management of adolescent depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32020643" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Annual Research Review: Defining and treating pediatric treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32020643" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Annual Research Review: Defining and treating pediatric treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15702497" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Suicidality in adolescents being treated with antidepressant medications and the black box label: position paper of the Society for Adolescent Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15702497" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Suicidality in adolescents being treated with antidepressant medications and the black box label: position paper of the Society for Adolescent Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36651686" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29358037" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30388048" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Psychometric Properties of the Patient Health Questionnaire-9 Modified for Major Depressive Disorder in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869927" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The patient health questionnaire for adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869927" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The patient health questionnaire for adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23702448" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Early menarche and depressive symptoms from adolescence to young adulthood in a UK cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880127" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence and characteristics of depressive disorders in early adolescents in central Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7759594" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Properties of the mood and feelings questionnaire in adolescent psychiatric outpatients: a research note.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24749755" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Validity of the Short Mood and Feelings Questionnaire in late adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37159676" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A17): A Psychometric Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37159676" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A17): A Psychometric Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37159676" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A17): A Psychometric Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37159676" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A17): A Psychometric Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18314433" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18281410" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
